• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种靶向 PPARγ 核心抑制剂选择性反向激动剂的结构机制。

A structural mechanism for directing corepressor-selective inverse agonism of PPARγ.

机构信息

Department of Integrative Structural and Computational Biology, The Scripps Research Institute, Jupiter, FL, 33458, USA.

Skaggs Graduate School of Chemical and Biological Sciences, The Scripps Research Institute, Jupiter, FL, 33458, USA.

出版信息

Nat Commun. 2018 Nov 8;9(1):4687. doi: 10.1038/s41467-018-07133-w.

DOI:10.1038/s41467-018-07133-w
PMID:30409975
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6224492/
Abstract

Small chemical modifications can have significant effects on ligand efficacy and receptor activity, but the underlying structural mechanisms can be difficult to predict from static crystal structures alone. Here we show how a simple phenyl-to-pyridyl substitution between two common covalent orthosteric ligands targeting peroxisome proliferator-activated receptor (PPAR) gamma converts a transcriptionally neutral antagonist (GW9662) into a repressive inverse agonist (T0070907) relative to basal cellular activity. X-ray crystallography, molecular dynamics simulations, and mutagenesis coupled to activity assays reveal a water-mediated hydrogen bond network linking the T0070907 pyridyl group to Arg288 that is essential for corepressor-selective inverse agonism. NMR spectroscopy reveals that PPARγ exchanges between two long-lived conformations when bound to T0070907 but not GW9662, including a conformation that prepopulates a corepressor-bound state, priming PPARγ for high affinity corepressor binding. Our findings demonstrate that ligand engagement of Arg288 may provide routes for developing corepressor-selective repressive PPARγ ligands.

摘要

小的化学修饰可以对配体的功效和受体活性产生重大影响,但仅从静态晶体结构很难预测潜在的结构机制。在这里,我们展示了如何通过在两种靶向过氧化物酶体增殖物激活受体 (PPAR)γ 的常见共价正位配体之间进行简单的苯基到吡啶基取代,将转录中性拮抗剂 (GW9662) 转化为相对于基础细胞活性的抑制性反向激动剂 (T0070907)。X 射线晶体学、分子动力学模拟以及与活性测定相结合的突变分析揭示了一个由水介导的氢键网络,将 T0070907 的吡啶基团与 Arg288 连接起来,对于核心抑制剂选择性的反向激动作用至关重要。NMR 光谱揭示了当与 T0070907 结合时,PPARγ 在两种长寿命构象之间交换,但与 GW9662 结合时则不会,包括一种预先存在的核心抑制剂结合状态的构象,使 PPARγ 能够与高亲和力的核心抑制剂结合。我们的研究结果表明,Arg288 的配体结合可能为开发核心抑制剂选择性抑制性 PPARγ 配体提供途径。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12e1/6224492/b41a5452d158/41467_2018_7133_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12e1/6224492/2c9be020f4bc/41467_2018_7133_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12e1/6224492/f3841718e2b1/41467_2018_7133_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12e1/6224492/d91a0fac060a/41467_2018_7133_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12e1/6224492/be57bfa02d8f/41467_2018_7133_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12e1/6224492/06f02b924f8c/41467_2018_7133_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12e1/6224492/c73ab73bb6ee/41467_2018_7133_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12e1/6224492/4435f3dadba9/41467_2018_7133_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12e1/6224492/b41a5452d158/41467_2018_7133_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12e1/6224492/2c9be020f4bc/41467_2018_7133_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12e1/6224492/f3841718e2b1/41467_2018_7133_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12e1/6224492/d91a0fac060a/41467_2018_7133_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12e1/6224492/be57bfa02d8f/41467_2018_7133_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12e1/6224492/06f02b924f8c/41467_2018_7133_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12e1/6224492/c73ab73bb6ee/41467_2018_7133_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12e1/6224492/4435f3dadba9/41467_2018_7133_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12e1/6224492/b41a5452d158/41467_2018_7133_Fig8_HTML.jpg

相似文献

1
A structural mechanism for directing corepressor-selective inverse agonism of PPARγ.一种靶向 PPARγ 核心抑制剂选择性反向激动剂的结构机制。
Nat Commun. 2018 Nov 8;9(1):4687. doi: 10.1038/s41467-018-07133-w.
2
A molecular switch regulating transcriptional repression and activation of PPARγ.一种调控 PPARγ 转录抑制和激活的分子开关。
Nat Commun. 2020 Feb 19;11(1):956. doi: 10.1038/s41467-020-14750-x.
3
Definition of functionally and structurally distinct repressive states in the nuclear receptor PPARγ.定义核受体 PPARγ 中具有不同功能和结构的抑制状态。
Nat Commun. 2019 Dec 20;10(1):5825. doi: 10.1038/s41467-019-13768-0.
4
Modification of the Orthosteric PPARγ Covalent Antagonist Scaffold Yields an Improved Dual-Site Allosteric Inhibitor.正构PPARγ共价拮抗剂支架的修饰产生了一种改进的双位点变构抑制剂。
ACS Chem Biol. 2017 Apr 21;12(4):969-978. doi: 10.1021/acschembio.6b01015. Epub 2017 Feb 16.
5
T0070907, a selective ligand for peroxisome proliferator-activated receptor gamma, functions as an antagonist of biochemical and cellular activities.T0070907是过氧化物酶体增殖物激活受体γ的选择性配体,具有生化和细胞活性拮抗剂的作用。
J Biol Chem. 2002 May 31;277(22):19649-57. doi: 10.1074/jbc.M200743200. Epub 2002 Mar 4.
6
PPARγ Corepression Involves Alternate Ligand Conformation and Inflation of H12 Ensembles.PPARγ 共抑制涉及配体构象的改变和 H12 集合的膨胀。
ACS Chem Biol. 2023 May 19;18(5):1115-1123. doi: 10.1021/acschembio.2c00917. Epub 2023 May 5.
7
Defining a conformational ensemble that directs activation of PPARγ.定义一个构象集合,指导 PPARγ 的激活。
Nat Commun. 2018 May 4;9(1):1794. doi: 10.1038/s41467-018-04176-x.
8
Chemical Crosslinking Mass Spectrometry Reveals the Conformational Landscape of the Activation Helix of PPARγ; a Model for Ligand-Dependent Antagonism.化学交联质谱揭示了 PPARγ 激活螺旋的构象景观;配体依赖性拮抗作用的模型。
Structure. 2018 Nov 6;26(11):1431-1439.e6. doi: 10.1016/j.str.2018.07.007. Epub 2018 Aug 23.
9
Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662.GW9662对过氧化物酶体增殖物激活受体配体结合位点中半胱氨酸修饰的功能影响。
Biochemistry. 2002 May 28;41(21):6640-50. doi: 10.1021/bi0159581.
10
Unanticipated mechanisms of covalent inhibitor and synthetic ligand cobinding to PPARγ.共价抑制剂与合成配体共结合至PPARγ的意外机制。
bioRxiv. 2024 Sep 12:2024.05.15.594037. doi: 10.1101/2024.05.15.594037.

引用本文的文献

1
Structural Basis of PPARγ-Mediated Transcriptional Repression by the Covalent Inverse Agonist FX-909.共价反向激动剂FX-909介导PPARγ转录抑制的结构基础
J Med Chem. 2025 Aug 28;68(16):17587-17597. doi: 10.1021/acs.jmedchem.5c01252. Epub 2025 Aug 12.
2
extracts enhance 3T3-L1 adipocyte differentiation via CHOP inhibition and PPARγ activation.提取物通过抑制CHOP和激活PPARγ增强3T3-L1脂肪细胞分化。
Anim Cells Syst (Seoul). 2025 Jul 25;29(1):469-487. doi: 10.1080/19768354.2025.2536022. eCollection 2025.
3
Structural basis of PPARγ-mediated transcriptional repression by the covalent inverse agonist FX-909.

本文引用的文献

1
Chemical Crosslinking Mass Spectrometry Reveals the Conformational Landscape of the Activation Helix of PPARγ; a Model for Ligand-Dependent Antagonism.化学交联质谱揭示了 PPARγ 激活螺旋的构象景观;配体依赖性拮抗作用的模型。
Structure. 2018 Nov 6;26(11):1431-1439.e6. doi: 10.1016/j.str.2018.07.007. Epub 2018 Aug 23.
2
PPARγ in Complex with an Antagonist and Inverse Agonist: a Tumble and Trap Mechanism of the Activation Helix.与拮抗剂和反向激动剂结合的PPARγ:激活螺旋的翻转和捕获机制
iScience. 2018 Feb 27;5:69-79. doi: 10.1016/j.isci.2018.06.012. Epub 2018 Jul 2.
3
Defining a conformational ensemble that directs activation of PPARγ.
共价反向激动剂FX-909介导的PPARγ转录抑制的结构基础
bioRxiv. 2025 May 8:2025.05.04.651770. doi: 10.1101/2025.05.04.651770.
4
Disrupting lipid homeostasis with CAV2 in OSCC triggers apoptosis, lipolysis, and mitochondrial dysfunction by transcriptional repression of PPARγ.在口腔鳞状细胞癌中,通过CAV2破坏脂质稳态会通过PPARγ的转录抑制触发细胞凋亡、脂解作用和线粒体功能障碍。
Cell Biosci. 2025 May 14;15(1):59. doi: 10.1186/s13578-025-01399-6.
5
PPAR-γ in Melanoma and Immune Cells: Insights into Disease Pathogenesis and Therapeutic Implications.黑色素瘤与免疫细胞中的过氧化物酶体增殖物激活受体γ:对疾病发病机制及治疗意义的见解
Cells. 2025 Apr 2;14(7):534. doi: 10.3390/cells14070534.
6
Identification of PTGR2 inhibitors as a new therapeutic strategy for diabetes and obesity.鉴定前列腺素还原酶2(PTGR2)抑制剂作为糖尿病和肥胖症的一种新治疗策略。
EMBO Mol Med. 2025 May;17(5):938-966. doi: 10.1038/s44321-025-00216-4. Epub 2025 Mar 21.
7
Ligand efficacy shifts a nuclear receptor conformational ensemble between transcriptionally active and repressive states.配体效力使核受体构象集合在转录活性状态和抑制状态之间转变。
Nat Commun. 2025 Feb 28;16(1):2065. doi: 10.1038/s41467-025-57325-4.
8
SETDB1 amplification in osteosarcomas: Insights from its role in healthy tissues and other cancer types.骨肉瘤中SETDB1基因扩增:基于其在健康组织及其他癌症类型中作用的见解
Oncotarget. 2025 Feb 12;16:51-62. doi: 10.18632/oncotarget.28688.
9
PPARγ modulator predictor (PGMP_v1): chemical space exploration and computational insights for enhanced type 2 diabetes mellitus management.过氧化物酶体增殖物激活受体γ调节剂预测器(PGMP_v1):用于改善2型糖尿病管理的化学空间探索与计算洞察
Mol Divers. 2025 Feb 1. doi: 10.1007/s11030-025-11118-5.
10
Unanticipated mechanisms of covalent inhibitor and synthetic ligand cobinding to PPARγ.意想不到的共价抑制剂和合成配体与 PPARγ 共结合的机制。
Elife. 2024 Nov 18;13:RP99782. doi: 10.7554/eLife.99782.
定义一个构象集合,指导 PPARγ 的激活。
Nat Commun. 2018 May 4;9(1):1794. doi: 10.1038/s41467-018-04176-x.
4
Genomic Activation of Reveals a Candidate Therapeutic Axis in Bladder Cancer.[基因名称]的基因组激活揭示了膀胱癌中的一个候选治疗轴。 (你原文中“of ”后面缺少具体内容,请补充完整以便准确翻译)
Cancer Res. 2017 Dec 15;77(24):6987-6998. doi: 10.1158/0008-5472.CAN-17-1701. Epub 2017 Sep 18.
5
A Slow Conformational Switch in the BMAL1 Transactivation Domain Modulates Circadian Rhythms.BMAL1反式激活结构域中的缓慢构象转换调节昼夜节律。
Mol Cell. 2017 May 18;66(4):447-457.e7. doi: 10.1016/j.molcel.2017.04.011. Epub 2017 May 11.
6
The Necessary Nitrogen Atom: A Versatile High-Impact Design Element for Multiparameter Optimization.必要的氮原子:多参数优化的多功能高影响力设计元素。
J Med Chem. 2017 May 11;60(9):3552-3579. doi: 10.1021/acs.jmedchem.6b01807. Epub 2017 Feb 8.
7
Modification of the Orthosteric PPARγ Covalent Antagonist Scaffold Yields an Improved Dual-Site Allosteric Inhibitor.正构PPARγ共价拮抗剂支架的修饰产生了一种改进的双位点变构抑制剂。
ACS Chem Biol. 2017 Apr 21;12(4):969-978. doi: 10.1021/acschembio.6b01015. Epub 2017 Feb 16.
8
Probing the Complex Binding Modes of the PPARγ Partial Agonist 2-Chloro-N-(3-chloro-4-((5-chlorobenzo[d]thiazol-2-yl)thio)phenyl)-4-(trifluoromethyl)benzenesulfonamide (T2384) to Orthosteric and Allosteric Sites with NMR Spectroscopy.利用核磁共振光谱探究PPARγ部分激动剂2-氯-N-(3-氯-4-((5-氯苯并[d]噻唑-2-基)硫代)苯基)-4-(三氟甲基)苯磺酰胺(T2384)与正构和变构位点的复杂结合模式。
J Med Chem. 2016 Nov 23;59(22):10335-10341. doi: 10.1021/acs.jmedchem.6b01340. Epub 2016 Nov 4.
9
PPARG Post-translational Modifications Regulate Bone Formation and Bone Resorption.过氧化物酶体增殖物激活受体γ(PPARG)的翻译后修饰调控骨形成与骨吸收。
EBioMedicine. 2016 Aug;10:174-84. doi: 10.1016/j.ebiom.2016.06.040. Epub 2016 Jun 29.
10
PPARγ helix 12 exhibits an antagonist conformation.过氧化物酶体增殖物激活受体γ螺旋12呈现出拮抗剂构象。
Phys Chem Chem Phys. 2016 Apr 7;18(13):9272-80. doi: 10.1039/c5cp06729d.